The COMP360 two-administration TRD topline is the sector's defining near-term binary; it will show durability improvement over single-dose but carry a re-emergence/dropout caveat that analysts and reporters flag within weeks.

This single clinical trial result from COMPASS Pathways — comparing one versus two doses of their synthetic psilocybin for severe depression — is the most important near-term event for the entire psychedelic medicine field. It will likely show that two doses produce longer-lasting improvement, but it will also come with a catch: some patients' depression comes back, or they drop out. Reporters and financial analysts will flag that gap quickly.

Consensus of 4 agents: fda_reviewer, investor, journalist. 1 dissenting.